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Abstract
Immunization with radiation attenuated Plasmodium sporozoites (RAS) elicits sterile protective immunity against sporozoite
challenge in murine models and in humans. Similarly to RAS, the genetically attenuated sporozoites (GAPs) named uis3(-),
uis4(-) and P36p(-) have arrested growth during the liver stage development, and generate a powerful protective immune
response in mice. We compared the protective mechanisms in P. yoelii RAS, uis3(-) and uis4(-) in BALB/c mice. In RAS and
GAPs, sterile immunity is only achieved after one or more booster injections. There were no differences in the immune
responses to the circumsporozoite protein (CSP) generated by RAS and GAPs. To evaluate the role of non-CSP T-cell
antigens we immunized antibody deficient, CSP-transgenic BALB/c mice, that are T cell tolerant to CSP, with P. yoelii RAS or
with uis3(-) or uis4(-) GAPs, and challenged them with wild type sporozoites. In every instance the parasite liver stage burden
was approximately 3 logs higher in antibody deficient CSP transgenic mice as compared to antibody deficient mice alone.
We conclude that CSP is a powerful protective antigen in both RAS and GAPs viz., uis3(-) and uis4(-) and that the protective
mechanisms are similar independently of the method of sporozoite attenuation.
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Introduction
To date only vaccines containing radiation attenuated sporozo-
ites (RAS) consistently induce sterile immunity in rodents [1],
monkeys [2] and humans [3]. Immunization of humans with
Plasmodium falciparum sporozoites was accomplished by the bite of
infected irradiated Anopheles mosquitoes, and after many booster
injections a high degree of protection was obtained [3,4]. The RAS
protective immunity is mediated by antibodies to sporozoites and by
effector CD4+ and CD8+ T cells against livers stages (exoerythro-
cytic stages or EEFs) [5]. The T cell protection is mediated in part
by interferon-c that promotes the production of NO in the infected
hepatocyte and subsequent inhibition of the development of the
early EEFs [6,7,8,9,10]. The antibodies are mostly or exclusively
directed against the circumsporozoite protein (CSP) that covers the
plasma membrane of the sporozoites [11]. These antibodies
immobilize sporozoites [12], prevent their attachment to the host’s
hepatocytes [13], and inhibit infection. Since the sporozoites
delivered by mosquito bite remain for a short time in the skin
[14] andintheblood circulation[15], the titersof antibodies toCSP
have to be very high to neutralize the infectivity of all incoming
parasites. Therefore CD4+ and/or CD8+ effector T cells that
recognize the infected hepatocytes are required to obtain sterile
immunity in the murine models of pre-erythrocytic vaccines [16].
In addition to RAS, advances in reverse genetics led to the
generation of the genetically attenuated parasites (GAP). The
attenuated parasites named uis3(-), uis4(-), P36p(-) [17–21] were
obtained by targeting sporozoite genes that are essential for
completing the liver stage cycle. Recent studies using RAS
immunization of CSP-transgenic BALB/c and C57BL/6 mice
that are unable to make antibody responses showed that CSP is a
powerful protective T cell antigen [22]. This apparent dominance
was also documented recently in Toxoplasma. Among thousands of
parasite proteins, only GRA6 generated a dominant CD8+
protective epitope [23]. It is known that T cells play a major
role in GAP-mediated protection, but the corresponding antigens
have not yet been identified [20,24,25]. This is highly desirable in
order to establish correlates of protection following human vaccine
trials. As a step in this direction, here we study the role of CSP in
the immune responses of mice to P. yoelii uis3(-) and uis4(-) GAPs.
Results
Groups of BALB /c mice were primed and boosted 14 days later
with 10
5 P. yoelii RAS, or with 10
5 P. yoelii uis3(-) or with uis4(-)
GAPs. All animals were challenged a week later with 1610
4 wild
type infectious sporozoites. The liver stage burdens were evaluated
byq-RTPCRat42 hourspostinfectionwhenthe EEFsaremature.
We found that the levels of protection elicited by RAS or GAP
vaccination were greater than 95% in all groups (Fig 1A). The anti-
CSP antibody titers measured by ELISA against the repeat domain
of the P. yoelii CSP ranged between 12,500 and 50,000 in all
immunized mice (Fig 1B). To compare the neutralizing activity of
the antibodies, P. yoelii salivary gland sporozoites were incubated
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and injected into naı ¨ve mice and the liver stage burden was
evaluated. In every instance the liver stage burdens were 8–9 fold
lower than that of sporozoites inoculated with normal mouse serum
(Fig 1C). The abundance of interferon-c producing CD8+ T cells
against the H2-K
d CTL epitope of CSP was evaluated by ex-vivo
ELISPOT assay. The T cell responses amongst different groups of
immunized mice were indistinguishable (Fig 1D). Therefore,
irrespective of how the sporozoites were attenuated, the overall
immune response of BALB/c mice directed against epitopes in CSP
was very similar.
Next we compared the relative importance of CSP in the
protective T cell responses to RAS and GAPs. For this purpose we
used BALB/c mice that are both T-cell tolerant to CSP and
cannot make antibodies [(CSP-transgenic, JhT (2/2)]. The mice
were primed and boosted with RAS, or with uis3(-) or uis4(-) GAPs
and challenged as above. We found that immunization with RAS
or GAPs led to a reversal of protection by approximately 3 logs in
CSP-transgenic, JhT (2/2) mice (Fig 2A), as compared to liver
stage burden of an identically immunized JhT (2/2) mice.
Further, RAS or GAP immunization in Jht (2/2) mice induced
very similar numbers of interferon-c producing T cells against the
CD8+ T cell epitope of CSP (Fig 2B).
In order to obtain sterile immunity by RAS in mice at least one
booster injections are generally required. In humans, complete
protection against challenge was achieved only after many boosters
over several months of P. falciparum infected and irradiated
mosquitoes [4]. Similarly, GAP immunization with P. yoelli uis3(-)
[20] or P. berghei uis3(-) [17] or P. berghei uis4(-) [18] only leads to
complete protection after one or more booster injections. In contrast
with these findings, it has been reported that BALB/cJ mice (Jackson
labs) were completely protected by single dose immunizations with
50,000 P. yoelii uis4(-) sporozoites [20]. We repeated the same
immunization protocol but used instead BALB/c mice bought from
Figure 1. Protective immune responses are conserved in P. yoelli RAS and uis3(-), uis4(-) GAPs. Comparative analysis of protective immune
response in BALB/cAnN mice following priming and boosting with 1610
5 P. yoelli RAS or with uis3(-) or with uis4(-) GAPs. All mice were challenged
with 1610
4 wild type infectious sporozoites and infected livers were isolated 42 hours post infection. (A) Liver stage burden in indicated groups of
immunized mice were assessed by measuring the parasite specific 18S rRNA copy numbers by q-RT PCR. (B) CS-specific antibody response in
indicated groups of immunized mice. (C) Liver stage burden in mice that received wild type P. yoelli sporozoites following neutralization with sera
obtained from naı ¨ve or indicated groups of immunized mice. (D) IFN-gamma ELISPOT assay to quantify CS specific T cells from indicated groups of
immunized mice. Results are expressed as mean6s.d of CS-specific CD8+ T cells obtained from 5 immunised mice per group. In (A) and (C) results are
expressed as mean6s.d of 18S r RNA copy numbers from 5 mice per group.
doi:10.1371/journal.pone.0004480.g001
Immunity against RAS and GAPs
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background than BALB/cJ. As shown in Table 1 all immunized
mice were infected after challenge, and there wasa minimum delay in
the pre-patent periods as compared to non-immunized controls. To
evaluate the innate susceptibility of the two BALB/c substrains to P.
yoelii s p o r o z o i t e s ,t h em i c ew e r ei vi n j e c t e dw i t h1 610
6 GFP-labeled
parasites [26]. As assessed by microscopy or by fluorescence activated
cell sorting of GFP+ infected hepatocytes, there were fewer numbers
(10–15 fold) of liver stages in the BALB/cJ (Jackson) mice as
compared to the BALB/cAnN (Taconic) (Sebastian A. Mikolajczak,
Alice S. Tarun, Nelly Camargo, Mehdi Labaied, and Stefan HI
Kappe, unpublished observations). Therefore, the previously ob-
served sterile protection of BALB/cJ mice by a single immunization
with uis4(-) [20] might be attributed to the decreased innate
susceptibility of these mice to P. yoelli sporozoites. The underlying
basis for the remarkable differences in the sporozoite infectivity for
BALB/cJ and BALB/cAnN mice is under investigation.
Discussion
Previous studies highlighted the central role of CD8+ T cells in
protection of BALB/c mice after vaccination with P. yoelii uis3(-),
uis4(-) [20], and of C57BL/6 mice with P. berghei uis3(-), uis4(-)
[24] and P36p(-) [19] GAPS, but the respective protective
antigen(s) have yet to be identified. The main finding of this
paper is that the humoral and cellular responses of BALB/c mice
to CSP by immunization with P. yoelii RAS, or uis3(-) or uis4(-)
GAPs are indistinguishable. We also show that in these three
experimental models CSP is a powerful protective T cell antigen.
Indeed, there was a profound reversal of protection (by
approximately 1,000 times) in immunized BALB/c mice that are
CSP transgenic (T cell tolerant to CSP) and JhT (2/2) (unable to
make antibodies).
Under natural conditions liver stages are very rare among the
massivenumbers of hepatocytesin the liver, and the development of
the parasite is completed in a few days. Thus, effector CD4+ or
CD8+ T cells have only a limited time to find and destroy the very
few infected hepatocytes prior to the completion of development of
theliver stagesandtheentry ofthousandsofmerozoitesintheblood
circulation. Furthermore, sporozoites remain in the skin and in the
blood circulation for a few hours, and neutralizing antibodies also
have a limited period of time to prevent hepatocyte invasion.
What is then the explanation for the powerful antibody and T cell
protective responses directed against CSP following RAS or GAS
Table 1. Single immunization of BALB/cAnN mice with P. yoelli uis4(-) GAP does not induce sterile immunity.
S.No Group
Number of animals immunized/












2. Immunized with 5610
4 P. yoelli uis4(-) and challenged after 7 days 4/4
# 2.5–3 None
3. Immunized with 5610




Figure 2. CS is a powerful protective T cell antigen in both P. yoelli RAS and uis3(-), uis4(-) GAPs. BALB/c CS-Tg JhT (2/2) mice were
primed and boosted with 1610
5 P. yoelli RAS or with uis3(-) or with uis4(-) GAPs. All immunized mice were challenged with 1610
4 wild type infectious
sporozoites and infected livers were isolated 42 hours post infection (A) Liver stage burden in indicated groups of immunized mice were assessed by
measuring the parasite specific 18S rRNA copy numbers by q-RT PCR. The results are expressed as mean6s.d of 18S rRNA copy numbers from 5 mice
per group. (B) IFN-gamma ELISPOT assay to quantify CS specific T cells from indicated groups of JhT (2/2) immunized mice. Results are expressed as
mean6s.d of CS-specific CD8+ T cells obtained from 5 immunized mice per group.
doi:10.1371/journal.pone.0004480.g002
Immunity against RAS and GAPs
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presentation, and the central repeat domain of CSP is a potent B cell
immunogen. Antibodies to the repeats immobilize the parasite [12]
and inhibit the attachment and subsequent infection of the liver cells
[13]. CSP is synthesized in large amounts by salivary gland
sporozoites [27], and continues to be transcribed in the liver stages
[28]. It is continuously shed by sporozoites during their migration
through cells from the site of injection until they reach hepatocytes.
Therefore, CSP enters not only the blood circulation but is also
released into the cytoplasm of traversed cells where it can be
processed and presented to T cells. The C-terminus of CSP contains
a very powerful H2-Kd restricted CD8+ epitope [29], and a
‘‘promiscuous’’ or ‘‘HLA degenerate’’ CD4+ epitope [30].
Although our studies did not include immunization of mice with
another GAP, P36p(-), and is limited to BALB/c mice, on the basis
of the present findings, it is likely that CSP will also play a major
role in protection in those additional experimental models. In fact,
CSP is also a protective antigen not only in mice but also in
humans. To date, the only vaccine that has been proven to be
effective in naı ¨ve human volunteers and in endemic areas is RTS,S
that contains the repeats and the C-terminus of the CSP of P.
falciparum [31]. We emphasize, however, that CSP is not the sole
protective T cell immunogen present in RAS or GAPs. As shown
elsewhere, after priming and two booster injections with RAS
transgenic CSP mice can be fully protected against challenge [22].
Consistent with these observations was a recent study that
demonstrated that sterile protection against malaria is independent
of immune responses to the circumsporozoite protein [32]. In this
study, P.berghei RAS immunized mice were challenged with a
transgenic P.berghei line expressing heterologous CSP from P.
falciparum [PfCS]. Complete sterile protection of P.berghei RAS
immunized mice suggested that protection is independent of
immune targets from the immunodominant CSP of P.berghei. This
study together with ours [22], provide evidence for the presence of
hitherto uncharacterized antigens that can be targeted to induce
sterile immunity against malaria. However, if we consider the
stringent requirements for inhibition of sporozoite infectivity that
we mentioned above, we argue that the parasite contains only a
few effective T and B cell antigens. Our findings suggest that these
few non-CS antigens are shared between RAS and GAPs.
Materials and Methods
Growing and harvesting P. yoelli uis3(-), uis4(-) and wild
type sporozoites
Female Swiss Webster mice were infected with blood stages of
Py uis3(-), uis4(-) and wild type parasites to initiate a gametocyte
infection. Mice having 2–3% gametocytes were used for feeding
female Anopheles mosquitoes. The Institutional Animal Care and
Use Committee of New York University approved all experimen-
tal procedures involving mice. The mosquitoes were dissected on
day 8 to analyze their midgut infectivity. On day 14, the salivary
glands were dissected to harvest infective sporozoites. The uis3(-),
uis4(-) and wild type sporozoites were used for immunization
experiments. Radiation attenuation of the wild type sporozoites
were carried out by exposing them to 10,000 rads (cesium
radiation source) for 15 minutes.
Immunisation of BALB/c and CSP-transgenic JhT (2/2)
mice with RAS and GAPs
To study the comparative immune responses against P.yoelli
RAS and GAPs, BALB/cAnN (Taconic) mice were primed and
boosted with 1610
5 sporozoites. Similar immunization regimens
were performed in CS-Tg mice that are obtained in JhT (2/2)
background (antibody deficient mice) to evaluate the relevance of
pre-erythrocytic T cell antigens other than CS. Seven days after
final immunization, the mice were challenged with 1610
4 wild
type infectious sporozoites. Blood, spleen and liver samples were
harvested to analyze the anti-CS antibody levels, CS-specific T
cells responses and liver stage burden in all challenged mice. To
monitor sterile immunity after single immunization two groups of
BALB/cAnN mice were immunized with 5610
4 Py uis4(-)
sporozoites and challenged on either day 7 or day 14 with
1610
4 wild type P.yoelli sporozoites. Blood smears were made from
day 2 post infection to monitor the appearance of blood stage
parasites.
IFN-gamma ELISPOT assay
To quantify the CS-specific T cell responses induced following
immunization with RAS and GAP, splenocytes were obtained
from all immunized mice and assayed by ELISPOT following the
method described earlier [33]. For these assays we used MHC
compatible A20.2J cells coated with SYVPSAEQI peptide that
stimulate CS-specific CD8+ T cells to secrete IFN-gamma.
ELISA
Immune sera were obtained from different immunized groups
of mice and were assayed for CS specific antibody titers.
Recombinant GST fusion protein containing the B cell epitope
of circumsporozoite protein was used as coating antigen in ELISA
[22]. ELISA was performed essentially as described earlier [34].
Sporozoite Neutralization assay
To assess the ability of immune sera to neutralize the infectivity
of the sporozoites, 1610
5 wild type P. yoelli sporozoites were
incubated in the pooled immune sera obtained from different
groups of immunized BALB/c mice. The sporozoites were
incubated for 35 minutes at 37uC. Following neutralization
2610
4 sporozoites were injected intravenously into each naı ¨ve
mouse. Quantification of P. yoelli 18S rRNA copy number was
performed essentially as described earlier [35] except that a double
stranded-DNA specific iQ SYBR Green supermix was used to
detect the PCR product. The amounts of parasite-derived 18S
rRNA copies were determined from a standard curve, generated
with known amounts of 18S rRNA plasmid.
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